Big news: our prices just got a lot lower. Shop now|New here? Get up to $200 in welcome perks, valid for 14 days. Claim offer now
US shipping INCLUDED on orders above $200
Research Insights

All content and product details on this site are for educational purposes only. Products are for in-vitro studies (performed outside the body) and not FDA-approved for medical use. Any introduction into humans or animals is prohibited by law.

PT-141 Peptide: Bremelanotide as a Melanocortin Agonist

Nabiha Khalid
October 27, 2026
PT-141 Peptide: Bremelanotide as a Melanocortin Agonist

Brief Overview/Summary

Investigate studies on PT-141 peptide (Bremelanotide) and its activity at melanocortin receptors, particularly the melanocortin 4 receptor (MC4R).

Bremelanotide is a heptapeptide that was initially documented in the literature in 2003 with the investigational code PT-141. PT 141 is a synthetic peptide that activates the brain's melanocortin receptors, prompting the release of nitric oxide.

PT-141's Mechanism of Action: How This Melanocortin Receptor Agonist Works

PT-141 functions by activating particular melanocortin receptors in the brain, especially the melanocortin 4 receptor (MC4R). Upon delivery, PT-141 interacts with MC4R, resulting in the activation of subsequent signaling cascades. 

PT-141 Research Evidence

Clinical and preclinical studies have characterised bremelanotide's activity at melanocortin receptors and its pharmacokinetics. Study designs and populations varied; see the references below.

PT-141 in Melanocortin Receptor Research: Areas of Study

PT-141 is studied as a melanocortin receptor agonist, with most attention on the melanocortin 4 receptor (MC4R) in the brain and the signaling cascades activated downstream of it. Studies have also examined its effect on nitric oxide release.

Future: Emerging Applications and PT-141 Research Developments

Further investigation of PT-141's activity at melanocortin receptors, and of its long-term effects, is needed.

References

  1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003 Jun;994:96-102. doi: 10.1111/j.1749-6632.2003.tb03167.x. PMID: 12851303.

  2. Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clin Ther. 2017 Mar;39(3):514-526.e14. doi: 10.1016/j.clinthera.2017.01.018. PMID: 28189361.

  3. Miller MK, Smith JR, Norman JJ, Clayton AH. Expert opinion on existing and developing drugs to treat female sexual dysfunction. Expert Opin Emerg Drugs. 2018 Sep;23(3):223-230. doi: 10.1080/14728214.2018.1527901. PMID: 30251897.

Read more about peptides